Valuation: XBiotech Inc.

Market Cap 65.85M 58.46M 54.71M 49.59M 93.64M 6.35B 94.32M 657M 256M 3.24B 247M 242M 10.41B P/E 2024
-3.12x
P/E 2025 -1.6x
Enterprise Value -59.7M -52.99M -49.59M -44.95M -84.89M -5.75B -85.5M -596M -232M -2.94B -224M -219M -9.44B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
75.67%
Yield 2024 *
-
Yield 2025 -
1 day-0.92%
1 week-0.92%
Current month-1.37%
1 month-1.82%
3 months-10.37%
6 months-6.90%
Current year-9.62%
1 week 2.16
Extreme 2.16
2.2
1 month 2.13
Extreme 2.13
2.27
Current year 2.13
Extreme 2.13
2.73
1 year 2.09
Extreme 2.09
3.44
3 years 2.09
Extreme 2.09
9.96
5 years 2.09
Extreme 2.09
16.47
10 years 2.09
Extreme 2.09
26.4
Manager TitleAgeSince
Chief Executive Officer 48 2025-12-07
Director of Finance/CFO 42 2023-02-09
Chief Operating Officer - -
Director TitleAgeSince
Chairman 63 2005-03-21
Director/Board Member - 2025-06-23
Director/Board Member - 2025-06-23
Date Insider Type Main position Quantity % Market Cap. Importance
10/1/25 Free

Director

51,000 0.1673%
10/1/25 Free

Director

56,000 0.1837%
10/1/25 Free

Director

79,115 0.2595%
Change 5-day change 1-year change 3-year change Capi.($)
-0.92%-0.92%-18.80%-47.32% 66.46M
+4.16%+4.16%+49.37%+94.17% 74.31B
+2.76%-1.16%+23.05%+83.03% 56.95B
+0.24%-1.37%+4.08%+37.22% 48.3B
-3.76%-2.25%+329.09%+698.20% 44.51B
-2.30%-3.35%+26.81%+30.88% 43.8B
+0.31%-0.68%+5.30%+108.64% 41.12B
-0.11%+2.30%+9.19%+58.68% 31.07B
+4.51%+8.43%+37.27%+34.97% 28.97B
-1.96%-2.88%-8.97%-13.92% 24.53B
Average +0.29%-0.79%+45.64%+108.46% 39.36B
Weighted average by Cap. +0.77%-0.94%+56.81%+134.43%

Financials

2024 2025
Net sales - -
Net income -38.53M -34.2M -32.01M -29.01M -54.79M -3.71B -55.19M -384M -150M -1.89B -145M -142M -6.09B -45.54M -40.43M -37.83M -34.29M -64.76M -4.39B -65.23M -454M -177M -2.24B -171M -167M -7.2B
Net Debt -162M -144M -135M -122M -231M -15.66B -233M -1.62B -630M -7.99B -610M -597M -25.68B -126M -111M -104M -94.53M -179M -12.1B -180M -1.25B -487M -6.17B -471M -461M -19.85B
Projected Income Statement - Annual - XBiotech Inc.
Logo XBiotech Inc.
XBiotech Inc. is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies for treating a variety of diseases, such as inflammatory conditions like rheumatology, infectious disease, cardiovascular disease and cancer. The Company's True Human monoclonal antibodies are derived from human donors that mount a natural human immune response. The Company is focused on therapies that block a potent substance, known as interleukin-1 alpha (IL-1a), that mediates a number of pathophysiological processes including tissue breakdown (i.e. synovium, cartilage, bone), paraneoplastic angiogenesis and tumor stroma remodeling, formation of blood clots, malaise, muscle wasting and general inflammation. It has various candidate products, including Natrunix. It has a clinical-stage therapeutic for methicillin resistant Staphylococcus aureus (MRSA), and several pre-clinical-stage therapeutics, including an oral delivery antibody therapeutic for colon infection by C. difficile.
Employees
87
Date Price Change Volume
26-10-06 US$2.160 -0.92% 11,692
26-10-05 US$2.180 -0.46% 32,740
26-10-02 US$2.190 -0.45% 25,236
26-10-01 US$2.200 +0.46% 13,563
26-09-30 US$2.190 +0.46% 62,849
  1. Stock Market
  2. Stocks
  3. XBIT Stock